DULOXETINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Duloxetine Hydrochloride, and what generic alternatives are available?
Duloxetine Hydrochloride is a drug marketed by Actavis Elizabeth, Ajanta Pharma Ltd, Alembic, Alkem Labs Ltd, Anchen Pharms, Apotex, Aurobindo Pharma Ltd, Breckenridge, Cspc Ouyi, Hetero Labs Ltd Iii, Inventia, Lupin Ltd, Macleods Pharms Ltd, Marksans Pharma, Prinston Inc, Qingdao Baheal Pharm, Sun Pharm, Sunshine, Teva Pharms Usa, Torrent, Yaopharma Co Ltd, Zydus Hlthcare, and Zydus Pharms. and is included in twenty-three NDAs.
The generic ingredient in DULOXETINE HYDROCHLORIDE is duloxetine hydrochloride. There are forty-two drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the duloxetine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Duloxetine Hydrochloride
A generic version of DULOXETINE HYDROCHLORIDE was approved as duloxetine hydrochloride by AUROBINDO PHARMA LTD on December 11th, 2013.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DULOXETINE HYDROCHLORIDE?
- What are the global sales for DULOXETINE HYDROCHLORIDE?
- What is Average Wholesale Price for DULOXETINE HYDROCHLORIDE?
Summary for DULOXETINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 23 |
NDAs: | 23 |
Finished Product Suppliers / Packagers: | 48 |
Raw Ingredient (Bulk) Api Vendors: | 118 |
Clinical Trials: | 356 |
Patent Applications: | 331 |
Formulation / Manufacturing: | see details |
DailyMed Link: | DULOXETINE HYDROCHLORIDE at DailyMed |
![DULOXETINE HYDROCHLORIDE drug patent expirations Drug patent expirations by year for DULOXETINE HYDROCHLORIDE](/p/graph/s/t/DULOXETINE_HYDROCHLORIDE-patent-expirations.png)
Recent Clinical Trials for DULOXETINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Beni-Suef University | Phase 2 |
National Cancer Institute, Egypt | Phase 4 |
GrĂ¼nenthal GmbH | Phase 3 |
Pharmacology for DULOXETINE HYDROCHLORIDE
Drug Class | Serotonin and Norepinephrine Reuptake Inhibitor |
Mechanism of Action | Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors |
Medical Subject Heading (MeSH) Categories for DULOXETINE HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for DULOXETINE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for DULOXETINE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CYMBALTA | Delayed-release Capsules | duloxetine hydrochloride | 40 mg | 021427 | 1 | 2012-05-10 |
CYMBALTA | Delayed-release Capsules | duloxetine hydrochloride | 20 mg, 30 mg and 60 mg | 021427 | 16 | 2008-08-04 |